Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Leases (2016 - 2017)

Historic Current Leases for Neurocrine Biosciences (NBIX) over the last 8 years, with Q4 2017 value amounting to $62000.0.

  • Neurocrine Biosciences' Current Leases fell 7372.88% to $62000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $62000.0, marking a year-over-year decrease of 7372.88%. This contributed to the annual value of $62000.0 for FY2017, which is 7372.88% down from last year.
  • Latest data reveals that Neurocrine Biosciences reported Current Leases of $62000.0 as of Q4 2017, which was down 7372.88% from $121000.0 recorded in Q3 2017.
  • Neurocrine Biosciences' 5-year Current Leases high stood at $556000.0 for Q2 2015, and its period low was $62000.0 during Q4 2017.
  • For the 5-year period, Neurocrine Biosciences' Current Leases averaged around $352900.0, with its median value being $412500.0 (2013).
  • As far as peak fluctuations go, Neurocrine Biosciences' Current Leases surged by 8438.66% in 2013, and later plummeted by 7372.88% in 2017.
  • Over the past 5 years, Neurocrine Biosciences' Current Leases (Quarter) stood at $416000.0 in 2013, then grew by 12.26% to $467000.0 in 2014, then fell by 8.35% to $428000.0 in 2015, then plummeted by 44.86% to $236000.0 in 2016, then crashed by 73.73% to $62000.0 in 2017.
  • Its last three reported values are $62000.0 in Q4 2017, $121000.0 for Q3 2017, and $181000.0 during Q2 2017.